AzTrials
AzTrials

Acute Kidney InjuryNCT03054142

China Collaborative Study on Epidemiology of Acute Kidney Injury

An observational study of Acute Kidney Injury, run by XinLing Liang at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Acute kidney injury (AKI) is a common clinical syndrome, especially patients in the hospital. AKI has become a huge medical burden in China. Little information is available about this disease burden in our country. The investigators aimed to evaluate the burden of AKI and to analyze the related risk factors. Read more about this study

Who is it for?
Any age
Conditions the study is for
Acute Kidney Injury
How many people
1,000,000 participants
Where
1 siteChina
Study dates
Jan 2017to 31 Dec 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: All inpatients (if outpatient identification is achieved, outpatient and inpatient patients can be judged to be the same individual, the outpatient electronic data is extracted at the same time)

Who may be able to join

  • The patients diagnosed on the basis of changes in serum creatinine according to the criteria of 2012 Kidney Disease Improving Global Outcomes(KDIGO)

Who cannot join

  • Serum creatinine record less than two times during hospitalization
  • Patients being diagnosed with End-stage kidney disease (chronic kidney disease stage 5)
  • Nephrectomy
  • Kidney transplantation
  • Peak serum creatinine of less than 53µ mol/L
  • Serum creatinine decrease after amputation

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Liang Xinling, M.D.,Ph.D contact

13808819770

xinlingliang@139.com

Liang Xinling, M.D.,Ph.D contact

86-13808819770

xinlingliang@139.com

China1 site, 1 recruiting
  • Nephrology Dept,Guangdong General Hospital

    Guangzhou, Guangdong

    Liang Xinling, MD,PhD, 86-13808819770, xinlingliang@139.com

    Recruiting

Other trials in China

About this study

Acute kidney injury (AKI) is a common clinical syndrome, especially patients in the hospital. AKI has become a huge medical burden in China. Little information is available about this disease burden in our country. The investigators aimed to evaluate the burden of AKI and to analyze the related risk factors.

Read the detailed description

The investigators launch a nationwide of all patients, who were admitted to hospital from 2011-2016. Patients were diagnosed on the basis of changes in serum creatinine by the laboratory information system. The investigators assessed rates of AKI according to the criteria of 2012 Kidney Disease Improving Global Outcomes (KDIGO).

Being tested
no intervention
Medical subject headings
Acute Kidney Injury

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • no interventionOther

Study groups in NCT03054142
Study groupRoleWhat they receive
AKINot described
Receives: Other: no intervention
non-AKINot described
Receives: Other: no intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of AKI

    Measured: Jan. 2011 to Oct. 2016

Secondary outcomes (5)
  1. Recognition rate of AKI

    Using machine learning and deep learning methods to establish AKI prediction model and risk models

    Measured: Jan. 2011 to Oct. 2016

  2. Proportion of nephrology referral

    Measured: Jan. 2011 to Oct. 2016

  3. In-hospital mortality

    Measured: Jan. 2011 to Oct. 2016

  4. Longer ICU stay

    Measured: Jan. 2011 to Oct. 2016

  5. Higher medical cost

    Measured: Jan. 2011 to Oct. 2016

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Feb 2017
  2. Study startJan 2017
  3. Primary completion31 Dec 2027 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Retrospective
Enrolment
1,000,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03054142
Sponsor's protocol ID
CCS-AKI RF2011-2016
Status last verified
Dec 2022
First submitted
13 Feb 2017
Last updated
13 Dec 2022
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Publications

  • Xu L, Wu Y, Chen Y, Li R, Wang Z, Li Z, Liu G, Yu L, Shi W, Liang X; China collaborative study on AKI (CCS-AKI). Is acute kidney injury age-dependent in older adults: an observational study in two centers from North China. BMC Geriatr. 2021 Jan 6;21(1):7. doi: 10.1186/s12877-020-01906-z.

    PubMed 33407184

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Kidney Injury, run by XinLing Liang at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Liang Xinling, M.D.,Ph.D (13808819770, xinlingliang@139.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of AKI (time frame: Jan. 2011 to Oct. 2016). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03054142, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Dec 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in